Table I.
Baseline patient characteristics.
| Variable | Conventional GVHD prophylaxis (n = 72) | Post-transplantation cyclophosphamide (n = 41) | P-value |
|---|---|---|---|
| Age, years; median (range) | 54 (19–74) | 50 (20–64) | 0.05 |
| Diagnosis, n (%) | |||
| AML/MDS | 30 (42%) | 15 (37%) | |
| ALL | 4 (6%) | 7 (17%) | |
| CLL | 10 (14%) | 3 (7%) | |
| CML/MPD | 8 (11%) | 2 (5%) | |
| Non-Hodgkin lymphoma | 14 (19%) | 8 (20%) | |
| Hodgkin lymphoma | 4 (6%) | 1 (2%) | |
| Aplastic Anaemia | 2 (3%) | 4 (10%) | |
| MM | 0 (0%) | 1 (2%) | |
| Lymphoid malignancies | 32 (44%) | 20 (49%) | 0.7 |
| Myeloid malignancies | 40 (56%) | 21 (51%) | |
| Disease risk index, n (%) | |||
| Very High | 9 (13%) | 6 (15%) | 0.4 |
| High | 19 (26%) | 13 (32%) | |
| Intermediate | 26 (36%) | 7 (17%) | |
| Low | 16 (22%) | 11 (27%) | |
| Missing | 2 (3%) | 4 (10%) | |
| Median (range) time to HCT from diagnosis, months | 27 (5–319) | 15 (3–162) | 0.3 |
| Donor/Recipient gender, n (%) | |||
| Female/Female | 9 (14%) | 13 (32%) | 0.3 |
| Female/Male | 18 (25%) | 7 (17%) | |
| Male/Female | 20 (28%) | 8 (20%) | |
| Male/Male | 25 (35%) | 13 (32%) | |
| Donor/Recipient CMV, n (%) | |||
| Non-reactive/Non-reactive | 5 (7%) | 2 (5%) | 0.5 |
| Reactive/Reactive | 26 (36%) | 14 (34%) | |
| Non-reactive/Reactive | 36 (50%) | 22 (54%) | |
| Reactive/Non-reactive | 5 (7%) | 3 (7%) | |
| Conditioning regimens, n (%) | |||
| Myeloablative | 36 (50%) | 23 (56%) | 0.5 |
| Reduced-intensity | 36 (50%) | 18 (44%) | |
| HLA mismatches | |||
| HLA class-I mismatch | 41 (57%) | 36 (88%) | <0.001 |
| HLA class-II mismatch | 31 (43%) | 5 (12%) | |
| Graft source, n (%) | |||
| Bone marrow | 45 (63%) | 34 (83%) | 0.02 |
| Peripheral blood | 27 (38%) | 7 (17%) | |
| Cell dose (bone marrow), median (range) | |||
| CD34+ (× 106/kg) | 2.4 (0.9–8.5) | 2.2 (0.7–7.63) | 0.3 |
| CD3+ (× 105/kg) | 17 (2.6–39) | 16 (0.9–47) | 0.2 |
| Cell dose (peripheral blood), median (range) | |||
| CD34+ (× 106/kg) | 6.44 (2.45–16) | 13.12 (3.5–41) | 0.06 |
| CD3+ (× 105/kg) | 154 (27–505) | 284 (86–381) | 0.2 |
| Median (range) number of prior chemotherapies | 2 (0–10) | 2 (0–7) | 0.4 |
| Prior autologous HCT, n (%) | |||
| None | 65 (90%) | 36 (88%) | |
| One | 7 (10%) | 4 (10%) | |
| Two | 0 (0%) | 1 (2%) | |
| Year of HCT, n (%) | |||
| 2009 | 18 (25%) | 1 (2%) | |
| 2010 | 21 (29%) | 9 (22%) | |
| 2011 | 18 (25%) | 13 (32%) | |
| 2012 | 10 (14%) | 14 (34%) | |
| 2013 | 5 (7%) | 4 (10%) | |
| Median (range) follow-up, in months | 24 (3–49) | 20 (4–43) |
AML, acute myeloid leukaemia; ALL, acute lymphoblastic leukaemia; CML, chronic myeloid leukaemia; CLL chronic lymphocytic leukaemia; CMV, Cytomegalovirus; GVHD, graft-versus-host disease; HLA, Human Leucocyte Antigen; HCT, haematopoietic stem cell transplantation; MDS, myelodysplastic syndrome; MM, multiple myeloma; MPD, myeloproliferative disorder.